NCT01040871 - Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma | Biotech Hunter

Enrollment

164

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

June 30, 2012

Study Completion Date

August 31, 2012

Conditions

Diffuse Large B-Cell Lymphoma

Interventions

DRUG

VELCADE

VELCADE intravenous on Days 1, 4, 8, and 11 of a 21 day (3 week) cycle for 6 cycles.

DRUG

Rituximab

Rituximab intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles

DRUG

Cyclophosphamide

Intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles

DRUG

Doxorubicin

Intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles

DRUG

Prednisone

Orally on Day 1 to Day 5 of a 21 day (3 week) cycle for 6 cycles

DRUG

Vincristine

Intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles

Trial Locations (1)

Universitair Ziekenhuis Gent - UZ GENT, Hematologie, 9K12IE 9de verdiep- polikliniek Hematologie, Ghent